<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Medicine</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/3AEB4C1F-38DA-4B07-8871-1DEBDF07BD1C"><gtr:id>3AEB4C1F-38DA-4B07-8871-1DEBDF07BD1C</gtr:id><gtr:firstName>Rachel</gtr:firstName><gtr:otherNames>Clare</gtr:otherNames><gtr:surname>Chambers</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/0683F1FE-75D3-4254-BC5A-0845CD7A2295"><gtr:id>0683F1FE-75D3-4254-BC5A-0845CD7A2295</gtr:id><gtr:firstName>Y C Gary</gtr:firstName><gtr:surname>Lee</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/ACE18B20-4218-4BD9-A733-D20E6FFAA05A"><gtr:id>ACE18B20-4218-4BD9-A733-D20E6FFAA05A</gtr:id><gtr:firstName>Jeremy</gtr:firstName><gtr:otherNames>Stuart</gtr:otherNames><gtr:surname>Brown</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0501557"><gtr:id>5B64AE38-A7F9-471D-8013-A7C5A36B193E</gtr:id><gtr:title>Thrombin &amp;amp; its Major Receptor in Transforming Growth Factor-beta Release and Adhesion Formation in Pleural Infection</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0501557</gtr:grantReference><gtr:abstractText>Pleural infection (commonly known as pleurisy) affects over 65,000 patients each year in the UK and USA, with a high mortality of 20%. Pleurisy is characterized by pus collection in the chest. Drainage of the pus is crucial to successful management, but is often difficult as pus is often locked into multiple pockets by fibrous septations. Understanding the pathophysiology of formation of these septations will allow strategies to target their formation. Our recent experiments suggest that pleurisy induces accumulation of thrombin (an enzyme involved in blood clotting) in the chest, which stimulates transforming growth factor (TGF)-beta release from mesothelial cells (that line the pleural cavity) in vitro. This is important as we have previously showed that TGF-beta can potently stimulate adhesions and fibrosis. 

The proposed project will bring together the expertise of five established researchers on TGF-beta and mesothelial cell biology (Dr Lee), PARs (Drs Chambers &amp;amp; Moffatt), pleural disease (Dr Davies) and pulmonary infection (Dr Brown). The proposed studies will build on our preliminary data and test the hypothesis that thrombin-induced release of TGF-beta plays an important role in the formation of adhesions / septations in pleurisy, using a variety of in vitro techniques and in vivo experimental models.</gtr:abstractText><gtr:technicalSummary>Pleural infection kills over 10,000 patients in the UK and USA annually. Pleural infection is characterized by fibrous adhesions/septations which prohibit evacuation of pus - resulting in ongoing sepsis. No effective medical therapy exist to reduce adhesion formation. 

We have shown that intrapleural administration of transforming growth factor (TGF)-beta potently induced collagen deposition and development of pleural adhesions. Active TGF-beta levels are significantly elevated in pleural fluid during pleural infection. What stimulates TGF-beta release during pleural infection is unknown. 

Extravasation and activation of coagulation factors is common following pleural injury. Our preliminary data suggest that intrapleural infection induces thrombin accumulation, and the major thrombin receptor, proteinase-activated receptor (PAR)-1, is expressed on pleural mesothelial cells. In vitro, thrombin stimulates TGF-beta release from cultured mesothelial cells. 
 
We hypothesize that pleural infection induces intrapleural accumulation of thrombin, which stimulates TGF-beta release from mesothelial cells, with resultant procollagen production and adhesion formation. The proposed study aims to show (i) that pleural infection leads to intrapleural accumulation of thrombin and TGF-beta; (ii) that thrombin induces mesothelial cell TGF-beta production via PAR1; and (iii) the effect of thrombin-induced TGF-beta on procollagen production and adhesion formation during pleural infection. 

Animal studies: (i) To define the effects of pleural infection on pleural accumulation of thrombin, TGF-beta and collagen, C57BL/6 mice will be inoculated intrapleurally with S. pneumoniae, S. aureus or saline. Thrombin, TGF-beta and procollagen peptide levels will be measured in the pleural lavage; and pleural adhesion assessed macroscopically and histologically. (ii) Wild type and PAR1-/- mice inoculated with bacteria will be treated with a thrombin inhibitor, a PAR1 antagonist, or an anti-TGF-beta antibody to confirm the ?necessity? of thrombin, PAR1 and TGF-beta in adhesion formation. In vitro studies: (i) To confirm that thrombin induces TGF-beta release via PAR1, mesothelial cells will be cultured with thrombin, with or without antagonists to PAR1 or its downstream mediators. Human studies: (i) To confirm the relevance of the experimental findings in humans, thrombin and TGF-beta levels will be measured in pleural fluid from patients with pleural infection, and correlated with disease severity. (ii) Human infective pleural fluid will be added to cultured mesothelial cells, with or without a thrombin inhibitor, PAR1 antagonist and anti-TGF-beta antibody. Procollagen synthesis and gene expression will be assessed.

This study will provide insight on the pathophysiology of pleural adhesion formation and may allow the design of strategies to inhibit adhesion formation to improve patient care.</gtr:technicalSummary><gtr:fund><gtr:end>2010-10-15</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-10-16</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>421044</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>AUD</gtr:currCode><gtr:currCountryCode>Australia</gtr:currCountryCode><gtr:currLang>en_AU</gtr:currLang><gtr:description>Project grant</gtr:description><gtr:end>2014-03-02</gtr:end><gtr:fundingOrg>Westcare Foundation</gtr:fundingOrg><gtr:id>1E499218-0001-4125-821C-59310F24603D</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>228751</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical PhD fellowship</gtr:description><gtr:end>2015-10-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>55AEFBAC-3977-4552-97E0-00DCF4DD0E7A</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>NICE pneumonia guidelines</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>CFCD830F-C8D0-49A0-A8CD-820E3FD0C669</gtr:id><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Lecture to GulfThoracic conference</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>13C71D1B-2BC8-412A-85AC-6A338446AC46</gtr:id><gtr:impact>I gave two lectures on the care of pneumonia patients at the GulfThoracic conference, Dubai; by educating the healthcare workforce these should improve provision of care for these patients in the Middle East</gtr:impact><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Clinical Reference Group membership</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>FBF0C2A1-781C-461D-BAD2-BED69F42968C</gtr:id><gtr:impact>responsible for the design and implementation of national commissioning for subspecialty care for specific areas of respiratory medicine- implemented subspecialty care for three separate conditions across England</gtr:impact><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Royal College Regional training day lectures (three in total, a fourth in Oct 2014)</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>1355A37A-4F60-485F-81BC-12AE6AA16E9E</gtr:id><gtr:impact>I have given 2012-2013 three lectures to Royal College of Physician regional training days on various aspects of clinical care for patients with pneumonia; a fourth lecture is planned for the national training conference October 2014</gtr:impact><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>we have developed a model of Streptococcus pneumoniae pneumonia that consistently results in empyema, allowing further research into the mechanisms involved.</gtr:description><gtr:id>1C3DB87E-3377-4C4B-8639-5A3E89DC2329</gtr:id><gtr:impact>None as yet, as the data has yet to be published.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>mouse model of post-pneumonic empyema</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F2E6FA15-17EF-4508-AEE6-7DB54EEABEB3"><gtr:id>F2E6FA15-17EF-4508-AEE6-7DB54EEABEB3</gtr:id><gtr:title>Characterization of a new mouse model of empyema and the mechanisms of pleural invasion by Streptococcus pneumoniae.</gtr:title><gtr:parentPublicationTitle>American journal of respiratory cell and molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/99447ff25c1e0d7c197698468605705d"><gtr:id>99447ff25c1e0d7c197698468605705d</gtr:id><gtr:otherNames>Wilkosz S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1044-1549</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0501557</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>